Latvija - latviešu - Zāļu valsts aģentūra

accord healthcare b.v., netherlands - ciklofosfamīds - pulveris injekciju/infūziju šķīduma pagatavošanai - 1000 mg

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

mylan ireland limited - fingolimod hidrohlorīds - multiplā skleroze, recidivējoši-pārskaitot - imūnsupresanti - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 un 5. 1)orpatients strauji attīstās smagas recidivējoši pārskaitot multiplā skleroze definēts 2 vai vairāk atspējošana recidīvu vienu gadu, un ar 1 vai vairāk gadolīnija uzlabot bojājumi uz smadzeņu mri vai ievērojami palielināt t2 bojājumu slodzes salīdzinājumā ar iepriekšējā pēdējo mr.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

mylan ireland limited - fingolimod hidrohlorīds - multiplā skleroze, recidivējoši-pārskaitot - imūnsupresanti - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 un 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

sanofi winthrop industrie - teriflunomīds - multiplā skleroze - selective immunosuppressants - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomīds - multiplā skleroze, recidivējoši-pārskaitot - imūnsupresanti - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomīds - multiplā skleroze, recidivējoši-pārskaitot - immunosuppressants, selektīvi immunosuppressants - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Latvija - latviešu - Zāļu valsts aģentūra

egis pharmaceuticals plc, hungary - teriflunomīds - apvalkotā tablete - 14 mg

Latvija - latviešu - Zāļu valsts aģentūra

stada arzneimittel ag, germany - teriflunomīds - apvalkotā tablete - 14 mg

Latvija - latviešu - Zāļu valsts aģentūra

sandoz d.d., slovenia - teriflunomīds - apvalkotā tablete - 14 mg

Latvija - latviešu - Zāļu valsts aģentūra

krka, d.d., novo mesto, slovenia - teriflunomīds - apvalkotā tablete - 14 mg